- Companies
- Medlinker
Medlinker Valuation, Funding & Investors
Medlinker is valued at $3.9B as of December 2021.
Last Medlinker valuation
$3.9B
Series E · Dec 2021
Last Medlinker funding round
$514M
Series E · Dec 2021
Cumulative funding Medlinker raised
$765M
across 7 funding rounds
Key investors in Medlinker
PreAngel
HSG
Tencent
YF Capital
China Renaissance
Huaxing Growth Capital
About Medlinker
Medlinker is a Shenzhen-based digital health platform connecting over 1.5 million Chinese physicians through social networking, case discussions, and quizzes. The app serves 5,000 hospitals with knowledge sharing, anonymous forums, and industry news for specialties like internal medicine. Listed on Hong Kong Stock Exchange in 2022, Medlinker reaches 300 million patients via telemedicine. Founded in 2014, it employs 2,000 staff.
Founded
2014
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$3.9B (Dec 2021)
Medlinker Valuation
Medlinker is currently valued at $3.9B, based on its Series E in December 2021.
The $514M round was led by Sino Biopharmaceutical.
Medlinker's valuation has grown 3.9x from $1B at its Series D in July 2018 to $3.9B in December 2021, across 2 priced rounds.
Medlinker valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Dec 2021 | Series E | $3.9B |
| Jul 2018 | Series D | $1B |
Medlinker Funding History
Medlinker has raised a total of $765M across 7 funding rounds.
Medlinker's first fundraising round was a $500K pre-seed round in May 2014. The most recent completed round was a $514M Series E in December 2021.
Medlinker funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Dec 2021 | Series E | Sino Biopharmaceutical (lead) | $514M | $3.9B | Medlinker is a Chinese B2X healthcare company founded in 2014, based in Chengdu, Sichuan, with 201-5000 employees and total funding of $761 million as of its latest round. It operates in the high-tech zone at No. 3, 2nd Floor, Building 6, No. 99 Tianhua 1st Road. The company previously reached unicorn status with over $1 billion valuation after a Series D round of 1 billion yuan ($151.9 million) led by CICFH. In December 2021, Medlinker completed its latest funding round of $514 million led by Sino Biopharmaceutical, achieving a post-money valuation of $3.9 billion. The company remains active. |
| Jul 2018 | Series D | China Capital Zhongcai Fund Management (lead); Huaxing Growth Capital; China Health Industry Investment Fund; HSG | $149M | $1B | Medlinker is a Chengdu-based medical technology company founded in 2014, operating a social media platform for verified physicians to share expertise with colleagues, healthcare providers, patients, pharmaceutical firms, and insurers. The platform connects over 500,000 verified doctors as of July 2018, up from 430,000 in 2017 and 100,000 registered users by 2015. It raised RMB 1 billion ($146-147.7 million) in its Series D round on July 31, 2018, led by China Capital Zhongcai Fund Management, with participation from China Health Industry Investment Fund, Sequoia Capital China, Huaxing Capital (China Renaissance), and HongShan (HSG). This Series D brought Medlinker's total funding to approximately $247.5 million at the time, following a $60 million Series C in December 2017 led by China Electronics Corporation Data with Tencent, Sequoia Capital China, and China Renaissance, a $40 million Series B led by Tencent in 2015, and earlier rounds from Sequoia, Ceyuan Ventures, and PreAngel. An April 2017 statement from Chengdu Tianfu Software Park cited Greatwall Strategy Consultants estimating Medlinker's valuation near RMB 5 billion, positioning it as a potential unicorn. The round supported growth in China's burgeoning medical technology sector, with Medlinker benefiting from Chengdu Hi-tech zone supports like rent reductions. |
| Dec 2017 | Series C | China Electronics Corporation (lead); Tencent; China Renaissance; HSG | $61M | - | Medlinker is a Chengdu-headquartered mobile platform and social network for physicians in China, connecting doctors, patients, hospitals, and insurers while offering services like case collection and partnerships for drug delivery and disease-specific solutions. It covers 34 provinces, serves over 25,000 hospitals, and had amassed over 130,000 cases from partners by late 2018. In December 2017, Medlinker raised RMB 400 million (about $60 million) in a Series C round led by China Electronics Corporation (CEC), with participation from Tencent, Sequoia Capital, and China Renaissance. This followed earlier rounds and preceded a Series D of RMB 1 billion ($147 million) backed by CIC Zhongcai, Sequoia Capital, and China Renaissance, with China Renaissance as financial advisor; the CEC partnership continued for new connectivity projects. An April 2017 statement from Chengdu Tianfu Software Park, citing Greatwall Strategy Consultants, estimated Medlinker's valuation near RMB 5 billion, positioning it as a potential unicorn, though not specified for the Series C. By July 2018, it achieved unicorn status with a valuation over $1 billion, and later rounds included a 2021 Series E at $514 million investment, reaching total funding of $764.74 million across rounds, culminating in a merger with Tencent Doctorwork. |
| Sep 2015 | Series B | YF Capital (lead) | $40M | - | - |
| Jun 2014 | Seed | PreAngel (lead) | $500K | - | - |
| May 2014 | Seed | Bo Feng (lead); PreAngel (lead) | $100K | - | - |
| May 2014 | Pre-seed | PreAngel (lead) | $500K | - | - |
Who has invested in Medlinker?
11 investors have backed Medlinker across its funding rounds, including PreAngel, HSG, Tencent, YF Capital, China Renaissance and Huaxing Growth Capital.
Lead investors include Sino Biopharmaceutical, China Capital Zhongcai Fund Management, China Electronics Corporation, YF Capital, PreAngel and 1 other investor.
Medlinker Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | May 2014 | ||
| 2 | Participant | Dec 2017 | ||
| 1 | Lead | Sep 2015 | ||
| 1 | Lead | May 2014 | ||
| 1 | Lead | Dec 2021 | ||
| 1 | Lead | Dec 2017 | ||
| 1 | Participant | Dec 2017 | ||
| 1 | Participant | Dec 2017 | ||
| 1 | Participant | Jul 2018 | ||
This data is available for Pro users. Sign up to see all 11 Medlinker investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Medlinker
Medlinker has acquired 1 company to date.
Last acquisition by Medlinker was on December 12th 2021. Medlinker acquired Xingren Doctor for undisclosed valuation.
Latest Acquisitions by Medlinker
| Description | Xingren Doctor is a medical application in China easing doctor workloads. It facilitates scheduling, note-taking, and patient communication amid high patient volumes. Beijing-launched in 2017, the app supports 50,000 physicians daily. |
| HQ Country | |
| HQ City | Shanghai |
| Deal Date | 12 Dec 2021 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Medlinker acquisitions and their M&A valuation multiples. Start Free Trial | |
Medlinker Competitors
Medlinker competitors include listed companies like Doximity and CCC Intelligent Solutions, and private ones like Olive, Aledade, Hippocratic AI and Innovaccer.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $645M | $229M | $4.7B | 6.2x | ||
| Publicly listed | $1.1B | $238M | $3.9B | 4.5x | ||
| Private | - | - | $4B | - | ||
| Private | $475M | - | $3.5B | 7.4x | ||
| Private | - | - | $3.5B | - | ||
| Private | $250M | - | $3.5B | 13.8x |
Medlinker Public Comps
Medlinker is still privately-owned, but its public comps include CCC Intelligent Solutions, JOYY, RUM Group, Life360, Doximity, Waystar, Strive, Grindr, Privia Health and Tieto.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.1B | $238M | 4.8x | 4.5x | 21.5x | 10.8x | |||
| $2.1B | $160M | 1.2x | 1.1x | 16.3x | 11.2x | |||
| $101M | ($78M) | 39.2x | 19.4x | (50.8x) | (70.5x) | |||
| $489M | $32M | 6.4x | 5.0x | 97.0x | 25.6x | |||
| $645M | $229M | 6.3x | 6.2x | 17.7x | 11.9x | |||
| $1.1B | $390M | 5.8x | 5.2x | 16.3x | 12.3x | |||
| $4M | ($21M) | 878.1x | 316.5x | (149.8x) | (64.9x) | |||
| $440M | $145M | 7.0x | 6.0x | 21.1x | 13.8x | |||
This data is available for Pro users. Sign up to see all Medlinker competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Medlinker
| When was Medlinker founded? | Medlinker was founded in 2014. |
| Where is Medlinker headquartered? | Medlinker is headquartered in Chengdu, China. |
| Is Medlinker publicly listed? | No, Medlinker is a private, VC-backed company. |
| What is Medlinker's valuation? | Medlinker was last valued at $3.9B in its Series E in December 2021. |
| How much funding has Medlinker raised? | Medlinker has raised $765M across 7 funding rounds. |
| What was Medlinker's last funding round? | Medlinker's last funding round was a $514M Series E in December 2021, led by Sino Biopharmaceutical. |
| Who are Medlinker's investors? | Medlinker's investors include PreAngel, HSG, YF Capital, Bo Feng, Sino Biopharmaceutical, China Electronics Corporation, Tencent, China Renaissance, Huaxing Growth Capital, China Capital Zhongcai Fund Management and 1 other. |
| Which companies are comparable to Medlinker? | Companies comparable to Medlinker include Doximity, CCC Intelligent Solutions, Olive, Aledade, Hippocratic AI and Innovaccer. |
| How many companies has Medlinker acquired? | Medlinker has acquired 1 company, including Xingren Doctor. |
See companies similar to Medlinker
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




